Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the Oxford University Clinical Research Unit in Vietnam have shown that using a rapid (5-minute) test can reduce antibiotic misuse for respiratory infections. Cutting the number of unnecessary antibiotic prescriptions is a key way to prevent the spread of antibiotic-resistant infections.

CTMGH logo for News

Researchers from the Oxford University Clinical Research Unit in Vietnam have shown that using a rapid (5-minute) test can reduce antibiotic misuse for respiratory infections. Cutting the number of unnecessary antibiotic prescriptions is a key way to prevent the spread of antibiotic-resistant infections.

The rapid tests detect C-reactive protein (CRP), a marker of infections caused by bacteria, in patients’ blood. A low level of CRP is suggestive of viral infection and therefore antibiotic treatment is not required.

The study team made the tests available at 10 primary healthcare centres in and around Hanoi, Vietnam, and recorded antibiotic use for 2000 patients who randomly were or were not tested for CRP. The results showed a significant reduction of antibiotic use in adults and children while clinical recovery was the same. This trial was the first to investigate this in a resource-constrained setting and showed similar results to trials in Europe. This was also the first trial to assess CRP tests for children.

Read more »

Similar stories

Supporting children to grow smarter, not just taller

EOCRU OUCRU

Anuraj Shankar from our EOCRU unit in Jakarta, Indonesia, with Elizabeth Prado and Leila Larson describe a meta-analysis showing that responsive caregiving boosts infants’ brain development. Parenting group sessions and home visits improve cognitive, language, and motor skills. And nutrition-only programmes have much less effect than comprehensive interventions.

Risks of serious adverse events following treatment for visceral leishmaniasis

OCGHR Publication Research

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.